194 related articles for article (PubMed ID: 34219594)
1. Potential alternatives to current cholinesterase inhibitors: an
Kundu D; Dubey VK
Drug Dev Ind Pharm; 2021 Jun; 47(6):919-930. PubMed ID: 34219594
[TBL] [Abstract][Full Text] [Related]
2. In silico repurposing of antipsychotic drugs for Alzheimer's disease.
Kumar S; Chowdhury S; Kumar S
BMC Neurosci; 2017 Oct; 18(1):76. PubMed ID: 29078760
[TBL] [Abstract][Full Text] [Related]
3. Drug repurposing for Alzheimer's disease:
Kumar N; Gahlawat A; Kumar RN; Singh YP; Modi G; Garg P
J Biomol Struct Dyn; 2022 Apr; 40(7):2878-2892. PubMed ID: 33170091
[TBL] [Abstract][Full Text] [Related]
4. De-novo Drug Design, Molecular Docking and In-Silico Molecular Prediction of AChEI Analogues through CADD Approaches as Anti-Alzheimer's Agents.
Pandey S; Singh BK
Curr Comput Aided Drug Des; 2020; 16(1):54-72. PubMed ID: 30827255
[TBL] [Abstract][Full Text] [Related]
5. A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease.
Korabecny J; Spilovska K; Mezeiova E; Benek O; Juza R; Kaping D; Soukup O
Curr Med Chem; 2019; 26(30):5625-5648. PubMed ID: 29768996
[TBL] [Abstract][Full Text] [Related]
6. In Silico Analysis of Green Tea Polyphenols as Inhibitors of AChE and BChE Enzymes in Alzheimer's Disease Treatment.
Ali B; Jamal QM; Shams S; Al-Wabel NA; Siddiqui MU; Alzohairy MA; Al Karaawi MA; Kesari KK; Mushtaq G; Kamal MA
CNS Neurol Disord Drug Targets; 2016; 15(5):624-8. PubMed ID: 26996169
[TBL] [Abstract][Full Text] [Related]
7. Screening and identification of secondary metabolites in the bark of
Khare N; Maheshwari SK; Jha AK
J Biomol Struct Dyn; 2021 Oct; 39(16):5988-5998. PubMed ID: 32720564
[TBL] [Abstract][Full Text] [Related]
8. BChE inhibitors from marine organisms - A review.
Lins Alves LK; Cechinel Filho V; de Souza RLR; Furtado-Alle L
Chem Biol Interact; 2022 Nov; 367():110136. PubMed ID: 36096160
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of imperatorin analogs and their evaluation as acetylcholinesterase and butyrylcholinesterase inhibitors.
Granica S; Kiss AK; Jarończyk M; Maurin JK; Mazurek AP; Czarnocki Z
Arch Pharm (Weinheim); 2013 Nov; 346(11):775-82. PubMed ID: 24123207
[TBL] [Abstract][Full Text] [Related]
10. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer's Disease.
Hussein W; Sağlık BN; Levent S; Korkut B; Ilgın S; Özkay Y; Kaplancıklı ZA
Molecules; 2018 Aug; 23(8):. PubMed ID: 30110946
[TBL] [Abstract][Full Text] [Related]
12. Highly potent and selective aryl-1,2,3-triazolyl benzylpiperidine inhibitors toward butyrylcholinesterase in Alzheimer's disease.
de Andrade P; Mantoani SP; Gonçalves Nunes PS; Magadán CR; Pérez C; Xavier DJ; Hojo ETS; Campillo NE; Martínez A; Carvalho I
Bioorg Med Chem; 2019 Mar; 27(6):931-943. PubMed ID: 30765302
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Novel Acetylcholinesterase Inhibitors as Potential Candidates for the Treatment of Alzheimer's Disease.
Son M; Park C; Rampogu S; Zeb A; Lee KW
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30823604
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of Benzimidazole-Based Analogs as Anti Alzheimer's Disease Compounds and Their Molecular Docking Studies.
Adalat B; Rahim F; Taha M; Alshamrani FJ; Anouar EH; Uddin N; Shah SAA; Ali Z; Zakaria ZA
Molecules; 2020 Oct; 25(20):. PubMed ID: 33092223
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease.
Liston DR; Nielsen JA; Villalobos A; Chapin D; Jones SB; Hubbard ST; Shalaby IA; Ramirez A; Nason D; White WF
Eur J Pharmacol; 2004 Feb; 486(1):9-17. PubMed ID: 14751402
[TBL] [Abstract][Full Text] [Related]
16. New cholinesterase inhibitors for Alzheimer's disease: Structure activity relationship, kinetics and molecular docking studies of 1-butanoyl-3-arylthiourea derivatives.
Larik FA; Shah MS; Saeed A; Shah HS; Channar PA; Bolte M; Iqbal J
Int J Biol Macromol; 2018 Sep; 116():144-150. PubMed ID: 29729344
[TBL] [Abstract][Full Text] [Related]
17. Combined QSAR, molecular docking and molecular dynamics study on new Acetylcholinesterase and Butyrylcholinesterase inhibitors.
Daoud I; Melkemi N; Salah T; Ghalem S
Comput Biol Chem; 2018 Jun; 74():304-326. PubMed ID: 29747032
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in Virtual Screening for Cholinesterase Inhibitors.
Miles JA; Ross BP
ACS Chem Neurosci; 2021 Jan; 12(1):30-41. PubMed ID: 33350300
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in silico investigation of FDA-approved drugs to be repurposed against Alzheimer's disease.
Akkaya D; Seyhan G; Sari S; Barut B
Drug Dev Res; 2024 May; 85(3):e22184. PubMed ID: 38634273
[TBL] [Abstract][Full Text] [Related]
20. Pursuing the Complexity of Alzheimer's Disease: Discovery of Fluoren-9-Amines as Selective Butyrylcholinesterase Inhibitors and
Konecny J; Misiachna A; Hrabinova M; Pulkrabkova L; Benkova M; Prchal L; Kucera T; Kobrlova T; Finger V; Kolcheva M; Kortus S; Jun D; Valko M; Horak M; Soukup O; Korabecny J
Biomolecules; 2020 Dec; 11(1):. PubMed ID: 33375115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
